Hematopoietic Stem Cell Expansion via MLPSC and HDACi
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding human hematopoietic stem cells (HSCs) in culture often result in the loss of primitive phenotype, limiting the availability of these cells for transplantation and gene therapy applications, and require well-matched donors, complicating the supply and genetic correction processes.
Innovation Solution
A method involving the culture of hematopoietic cells with mesenchymal lineage precursor or stem cells (MLPSCs) and histone deacetylase inhibitors (HDACi) to expand HSCs with specific phenotypes (CD34+, CD90+, CD45RA−, CD49f+) up to 100-fold, enabling ex vivo expansion and genetic manipulation for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If HSCs are expanded in culture, then the number of HSCs increases, but the primitive phenotype is lost
Solution Approach 1:
The patent applies parameter changes by modifying culture conditions through the addition of specific growth factors (SCF, FLT3-L, TPO), small molecules (SR1, UM171), and HDAC inhibitors to expand HSCs while maintaining primitive phenotype characteristics
Solution Approach 2:
The patent uses mesenchymal lineage precursor or stem cells (MLPSCs) as an intermediary to support HSC expansion and maintain their primitive phenotype during culture
2Quantity of substance
If donor supply is increased, then availability of HSCs for transplantation improves, but donor matching complexity increases
Solution Approach 1:
The patent enables self-service by allowing autologous HSC expansion where a patient's own HSCs are harvested, expanded ex vivo, and retransferred, eliminating the need for donor matching while increasing HSC availability
Solution Approach 2:
The patent applies preliminary action by expanding HSCs ex vivo before transplantation, creating a renewable supply that can be stored and used when needed, reducing reliance on immediate donor availability
3Productivity
If ex vivo expansion is achieved, then renewable therapeutic resource is established, but loss of stemness occurs
Solution Approach 1:
The patent maintains stemness during ex vivo expansion by carefully controlling culture parameters including growth factors, small molecules, and HDAC inhibitors to prevent differentiation while enabling proliferation
Solution Approach 2:
The patent uses MLPSCs as an intermediary culture support system that provides necessary signals to maintain HSC stemness characteristics during ex vivo expansion
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the number and availability of HSCs for transplantation and gene therapy, allowing for autologous transplants and expanding the use of umbilical cord blood in adult patients, while enabling genetic correction and expansion of HSCs for various hematologic disorders.
Implementation Method 1
at least one histone deacetylase inhibitor (HDACi) such that hematopoietic stem cells having the phenotype CD34+ are expanded
Data Source
AI summary
The present disclosure relates to methods and compositions for expansion of human hematopoietic stem cells. The present disclosure also relates to methods of treatment involving the use of the expanded HSCs.